Prism Review Media Group Prism Review Media Group
  • Business
  • Finance
  • Technology
  • Health
  • Culture
Subscribe
Search
Subscribe

Health

A Man Went to Hospital With Blood in His Urine. Doctors Found a Needle in His Heart.
HEALTH

A Man Went to Hospital With Blood in His Urine. Doctors Found a Needle in His Heart.

CARLY CASSELLA

September 12, 2026

AI-Designed Drug Makes Patients' Blood Look Biologically Younger, Study Shows
HEALTH

AI-Designed Drug Makes Patients' Blood Look Biologically Younger, Study Shows

ESRA ÖZ

September 12, 2026

Brutal beating: Man, 45, bumps into teen at state fair, then gang of a dozen 'kicked and stomped' on man's face, fiancée says | Blaze Media
HEALTH

Brutal beating: Man, 45, bumps into teen at state fair, then gang of a dozen 'kicked and stomped' on man's face, fiancée says | Blaze Media

HTTPS://WWW. FACEBOOK. COM/140738092630206

September 12, 2026

Baker Mayfield Career Timeline: How He Went From Browns No. 1 Pick to Buccaneers Franchise QB
HEALTH

Baker Mayfield Career Timeline: How He Went From Browns No. 1 Pick to Buccaneers Franchise QB

EVA GEITHEIM

September 12, 2026

Want to lower your risk of dementia? It doesn't involve a blood test
HEALTH

Want to lower your risk of dementia? It doesn't involve a blood test

THE ASSOCIATED PRESS

September 12, 2026

Browns GM Shuts Down DeShaun Watson Accusations
HEALTH

Browns GM Shuts Down DeShaun Watson Accusations

SEAN DEVENEY

September 12, 2026

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial
HEALTH

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

September 12, 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC
HEALTH

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

September 12, 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC
HEALTH

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

September 12, 2026

Previous Next
Prism Review Media Group

A premium editorial platform for executives, investors, and industry leaders who demand more from their reading. Rigorous journalism. Uncompromising standards.

  • LinkedIn
  • Twitter
  • Instagram
  • YouTube

Categories

  • Business
  • Culture
  • Health
  • Technology

Company

  • About Us
  • Contributors
  • Articles

Quick Links

  • Newsletter
  • Contact
  • Publishing Guidelines
  • Corrections Policy

© 2026 Prism Review Media Group. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Editorial Policy
  • Cookie Settings